Chaoliu Dai

机构：Technical University of Munich · ORCID：0000-0002-5122-2792

发表论文 75 篇 · 总被引 5224 次 · h-index 25

代表论文

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 513)
• Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) (2023 · Liver Cancer · 被引 465)
• MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis (2021 · EBioMedicine · 被引 289)
• Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) (2022 · HepatoBiliary Surgery and Nutrition · 被引 202)
• Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition) (2022 · Liver Cancer · 被引 111)
• AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy (2022 · Theranostics · 被引 59)